Press Releases
Press Releases
More Press Releases
View Older Stories View Newer Stories-
Option Care Health to Participate in Upcoming Investor Conferences
-
Lakeland Fire + Safety Declares Cash Dividend for Fourth Quarter 2026
-
Nyxoah to Participate in the Stifel 2025 Healthcare Conference
-
Protagonist Therapeutics Announces Oral and Poster Presentations on Rusfertide at the 67th Annual ASH Meeting
-
Castle Biosciences Launches AdvanceAD-Tx™ to Help Guide Systemic Treatment Decision Making in Patients with Moderate-to-Severe Atopic Dermatitis
-
NurExone Accepted into ARMI’s BioFab Startup Lab Strengthening U.S Position in Regenerative Manufacturing
-
Harmonic Expands Broadband Partnership with Spectrum Across Entire Subscriber Base
-
Kforce Reports Third Quarter 2025 Revenue of $332.6 Million and EPS of $0.63
-
Navitas Semiconductor Announces Third Quarter 2025 Financial Results
-
Phreesia Sets Release Date for Fiscal Third Quarter 2026 Results
-
Palm Club Design Group Opens Immersive New Jupiter Design Showroom
-
Vertex Reports Third Quarter 2025 Financial Results
-
Gibson Energy Declares Dividend
-
Kura Oncology Receives Second $30 Million Development Milestone Payment in AML Menin Inhibitor Program With Kyowa Kirin
-
Align Technology Opens 2026 Annual Research Program to Advance Orthodontic and Dental Patient Care
-
Inspire Medical Systems, Inc. Announces Third Quarter 2025 Financial Results and Updates 2025 Outlook
-
FibroGen to Report Third Quarter 2025 Financial Results
-
Sense Group Expands Service Coverage Across Ontario
-
Mdxhealth to Release Third Quarter 2025 Financial Results on November 12
-
SBA Communications Corporation Reports Third Quarter 2025 Results; Updates Full Year 2025 Outlook; and Declares Quarterly Cash Dividend
-
Transcat Reports Strong Fiscal Second Quarter 2026 Financial Results with Double-Digit Revenue & Gross Profit Growth
-
Hologic Announces Financial Results for Fourth Quarter of Fiscal 2025
-
SANMINA REPORTS FOURTH QUARTER AND FISCAL 2025 FINANCIAL RESULTS
-
Letter to Stockholders Issued by Diamondback Energy, Inc.
-
HALOZYME RAISES 2025 FINANCIAL GUIDANCE AND REPORTS STRONG THIRD QUARTER 2025 FINANCIAL AND OPERATING RESULTS
-
Shore Bancshares, Inc. Reports Quarterly Dividend of $0.12 Per Share
-
Super Group Reports Financial Results for Third Quarter of 2025
-
3-Year Renal Data in Adults with Hypoparathyroidism Treated with TransCon® PTH (Palopegteriparatide) to Be Shared at Kidney Week 2025
-
Xenon Reports Third Quarter 2025 Financial Results & Business Update
-
Thornburg Income Builder Opportunities Trust Announces Distribution
-
Veradigm Appoints Tehsin Syed as Chief Product and Technology Officer
-
MindMed Announces New Employee Inducement Grant
-
Diamondback Energy, Inc. Announces Third Quarter 2025 Financial and Operating Results
-
Letter to Stockholders Issued by Diamondback Energy, Inc.
-
Xenon Reports Third Quarter 2025 Financial Results & Business Update
-
Gibson Energy Delivers Record Throughput and Continued Growth Across Canadian and U.S. Terminals in Q3 2025
-
Syndax Reports Third Quarter 2025 Financial Results and Provides Business Update
-
Invivyd to Host Third Quarter 2025 Financial Results and Corporate Update Call on November 6, 2025
-
Viper Energy, Inc., a Subsidiary of Diamondback Energy, Inc., Reports Third Quarter 2025 Financial and Operating Results; Announces Divestiture of Non-Permian Assets
-
Forte Biosciences, Inc. to Present at Upcoming Healthcare Conferences
-
Symbotic Announces Date for Reporting Fourth Quarter and Fiscal Year 2025 Financial Results
-
Biodesix Announces Third Quarter 2025 Results and Highlights
-
Capital Southwest Announces Financial Results for Second Fiscal Quarter Ended September 30, 2025
-
Rapid7 Expands Partnership with Microsoft to Advance Modern Detection and Response
-
Galapagos to Present New Data from Cell Therapy Program at ASH 2025
-
Starkey Hearing Foundation Raises Awareness for Global Hearing Care Access at "An Intimate Evening With Elton"
-
Lattice Semiconductor Reports Record Communications & Computing Revenue in Third Quarter 2025
-
Tennant Company Reports Third Quarter 2025 Results
-
Physician and New York Times Best-Selling Author Dr. Michael Greger Offers CMEs
-
U.S. FDA approves KYGEVVI® (doxecitine and doxribtimine), the first and only treatment for adults and children living with thymidine kinase 2 deficiency (TK2d)
